Bioclone was formed in 1981 to take advantage of Australian expertise in medical research and biotechnology. A collaborative project between the CSIRO and the Garvan Institute for Medical Research gave Bioclone an excellent range of monoclonal antibodies to pituitary hormones from which diagnostic kits were later developed.
Bioclone specialises in the manufacture of high quality immunodiagnostic products for the medical and research laboratory markets. The core range of kits include kits for pregnancy, fertility monitoring, thyroid disease, anaemia, allergy, growth factors, prenatal and neonatal screening and some infectious diseases. Bioclone produces a large range of immunoassay products for the medical diagnostics market, marketed worldwide through a network of distributors.
Bioclone has continued to invest in innovation and new product development both through collaboration with research organisations and through its own Research and Development team. Contract manufacturing and development services are also available for: immunoassay kit manufacture; large-scale microtitre ELISA production; antibody production including bulk production of monoclonals; and immunoassay development (ELISA, IRMA, RIA, Chemiluminescent assays). The company's custom-designed facility for the development and manufacture of immunodiagnostic products operates under the Quality Management System umbrella of ISO9001 and is TGA certified for diagnostic manufacture.
In addition to marketing its own products, Bioclone acts as the Australian and New Zealand distributor for some selected overseas companies including: StressGen Biotechnology; Immune Source & Immuno-Quality (IQ) Products; Fitzgerald Industries International; Scripps Laboratories & BiosPacific; DIA.METRA; Cortex Biochem; RNAture; ScheBo Biotech; InnoGenex; and Osteometer BioTech.